These have revolutionized the treatment of CLL when prescribed as monotherapy, as is the case of BTK inhibitors (BTKi), or by combining a BTKi, such as ibrutinib, with the BCL-2 inhibitor, venetoclax.4,5. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.